[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 6, 1969

Renal Clearance in Man of Pharmaceuticals Containing Radioactive IodineInfluence of Plasma Binding

Author Affiliations

From the Section of Clinical Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minn.

JAMA. 1969;207(1):97-104. doi:10.1001/jama.1969.03150140049006
Abstract

Renal clearances of diatrizoate sodium I 125 or iothalamate sodium I 125 measure 90% to 100% of simultaneous classic clearances of inulin; clearances of iodohippurate sodium I 131 or iodopyracet I 131 are 84% and 79%, respectively, of simultaneous clearances of aminohippurate sodium. Plasma binding (8% to 27% of diatrizoate sodium I 125 or iothalamate sodium I 125; 64% to 70% of iodohippurate sodium I 131; 29% to 42% of iodopyracet I 131; 7% to 25% of aminohippurate) is revealed by ultrafiltration studies. Binding is labile and dissociable. Correcting clearances of diatrizoate sodium I 125 or iothalamate sodium I 125 for plasma binding yields values exceeding those of insulin clearances. Uncorrected, they are satisfactory substitutes for inulin clearance in man. Clearances of iodohippurate sodium I 131 or iodopyracet I 131 approximate adequately clearances of aminohippurate when carrier iodopyracet is added and the clearances are corrected for plasma binding to provide an estimate of total clearance.

×